Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 15:59:51 2024-05-24 EDT			5-day change	1st Jan Change
3.51 ^USD	-1.40%		-1.13%	-84.02%

05-14	Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tenax Therapeutics, Inc. Announces Addition of Barry Borlaug to Scientific Advisory Board

February 21, 2020 at 08:30 am

Tenax Therapeutics, Inc. announced that Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic has joined scientific advisory board.

Latest news about Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Tenax Therapeutics Secures Global Rights for Levosimendan	02-20	MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	02-20	CI
Top Midday Decliners	02-08	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	02-08	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	02-08	MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	02-08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	02-07	CI
Sector Update: Health Care Stocks Gain Late Afternoon	02-06	MT
Sector Update: Health Care	02-06	MT
Top Midday Gainers	02-06	MT
Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer	01-12	CI
Tenax Therapeutics, Inc. Announces Chief Financial Officer Changes	01-12	CI
Tenax Therapeutics to Implement 1-for-80 Reverse Stock Split	12-29	MT
Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board	11-17	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	11-13	MT
Sector Update: Health Care	11-13	MT
Top Midday Gainers	11-13	MT
Tenax Therapeutics Shares Double Premarket After FDA Clears IND for TNX-103	11-13	DJ
Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure	11-13	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-07-19	CI

Chart Tenax Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Companyâs other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.51 USD

Average target price

32.5 USD

Spread / Average Target

+825.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TENAX THERAPEUTICS, INC.	-84.02%	6.97M
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research